Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Characteristics of Trials Included in Meta‐Analysis

Article Snippet: REDUCE HTN: REINFORCE , RSCT , 2020 , 34/17 , 2 , rRDN , Vessix Renal Denervation system , United Sates , ... , ... , Office SBP >180 mm Hg at 2 consecutive visits within 3 d.

Techniques: Medications

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Primary outcome ascertainment time points: RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; TARGET BP OFF‐MED: 2 mo; and REDUCE HTN‐REINFORCE: 2 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: REDUCE HTN: REINFORCE , RSCT , 2020 , 34/17 , 2 , rRDN , Vessix Renal Denervation system , United Sates , ... , ... , Office SBP >180 mm Hg at 2 consecutive visits within 3 d.

Techniques:

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Primary outcome ascertainment time points: RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; TARGET BP OFF‐MED: 2 mo; and REDUCE HTN‐REINFORCE: 2 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: REDUCE HTN: REINFORCE , RSCT , 2020 , 34/17 , 2 , rRDN , Vessix Renal Denervation system , United Sates , ... , ... , Office SBP >180 mm Hg at 2 consecutive visits within 3 d.

Techniques:

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Primary outcome ascertainment time points: RADIANCE‐HTN TRIO: 2 mo; REQUIRE: 3 mo; SPYRAL‐HTN ON MED Expansion: 6 mo; WAVE IV: 6 mo; DENERHTN: 6 mo; SYMPATHY: 6 mo; ReSet: 6 mo; SYMPLICITY HTN‐III: 6 mo; SYMPLICITY HTN‐II: 6 mo; and Desch et al: 6 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: REDUCE HTN: REINFORCE , RSCT , 2020 , 34/17 , 2 , rRDN , Vessix Renal Denervation system , United Sates , ... , ... , Office SBP >180 mm Hg at 2 consecutive visits within 3 d.

Techniques:

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Primary outcome ascertainment time points: RADIANCE‐HTN TRIO: 2 mo; REQUIRE: 3 mo; SPYRAL‐HTN ON MED Expansion: 6 mo; WAVE IV: 6 mo; DENERHTN: 6 mo; SYMPATHY: 6 mo; ReSet: 6 mo; SYMPLICITY HTN‐III: 6 mo; SYMPLICITY HTN‐II: 6 mo; and Desch et al: 6 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: REDUCE HTN: REINFORCE , RSCT , 2020 , 34/17 , 2 , rRDN , Vessix Renal Denervation system , United Sates , ... , ... , Office SBP >180 mm Hg at 2 consecutive visits within 3 d.

Techniques:

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: In OFF‐Med trials, patients started without medications; antihypertensive medications were initiated after primary outcome assessment (RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; and TARGET BP OFF‐MED: 2 mo). Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: REDUCE HTN: REINFORCE , RSCT , 2020 , 34/17 , 2 , rRDN , Vessix Renal Denervation system , United Sates , ... , ... , Office SBP >180 mm Hg at 2 consecutive visits within 3 d.

Techniques: Medications

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: In OFF‐Med trials, patients started without medications; antihypertensive medications were initiated after primary outcome assessment (RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; and TARGET BP OFF‐MED: 2 mo). Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: REDUCE HTN: REINFORCE , RSCT , 2020 , 34/17 , 2 , rRDN , Vessix Renal Denervation system , United Sates , ... , ... , Office SBP >180 mm Hg at 2 consecutive visits within 3 d.

Techniques: Medications